Table 3. Further analysis of the CPV-2 positive samples.
| Harbin | Daqing | Mudanjiang | Total | ||||
|---|---|---|---|---|---|---|---|
| Numbers of sample | 141 | 20 | 40 | 201 | |||
| Positive rate for CPV-2 | 48.94% (69/141) | 30% (6/20) | 50% (20/40) | 47.26% (95/201) | |||
| Genotyping of CPV-2 | New2a | 62.32% (43/69) | 50% (3/6) | 75% (15/20) | 64.21% (61/95) | ||
| New2b | 24.64% (17/69) | 50% (3/6) | — | 21.05% (20/95) | |||
| 2c | 13.04% (9/69) | — | 25% (5/20) | 14.74% (14/95) | |||
| Substitution of amino acid residues in VP2 protein of CPV-2 | 297Ser/Ala | Ser | — | — | — | — | |
| Ala | 100% (69/69) | 100% (6/6) | 100% (20/20) | 100% (95/95) | |||
| 324Tyr/Ile | Tyr | — | — | — | — | ||
| Ile | 100% (69/69) | 100% (6/6) | 100% (20/20) | 100% (95/95) | |||
| 370Gln/Arg | Gln | 86.96% (60/69) | 100% (6/6) | 75% (15/20) | 85.26% (81/95) | ||
| Arg | 13.04% (9/69) | — | 25% (5/20) | 14.74% (14/95) | |||
| 419Asn/Ser | Asn | 95.65% (66/69) | 100% (6/6) | 100% (20/20) | 96.84% (92/95) | ||
| Ser | 4.35% (3/69) | — | — | 3.16% (3/95) | |||
| 440Thr/Ala | Thr | 27.54% (19/69) | 16.67% (1/6) | 70% (14/20) | 35.79% (34/95) | ||
| Ala | 72.46% (50/69) | 83.33% (5/6) | 30% (6/20) | 64.21% (61/95) | |||
| Vaccined | Yes | 44.93% (31/69) | 50% (3/6) | 60% (12/20) | 48.42% (46/95) | ||
| No | 30.43% (21/69) | 50% (3/6) | 35% (7/20) | 32.63% (31/95) | |||
| Collection data | Jan. to Mar. | 11.59% (8/69) | 33.33% (2/6) | 25% (5/20) | 15.78% (15/95) | ||
| Apr. to Jun. | 1.45% (1/69) | 16.67% (1/6) | 25% (5/20) | 7.37% (7/95) | |||
| Jul. to Sep. | 15.94% (11/69) | — | — | 11.58% (11/95) | |||
| Oct. to Dec. | 71.01% (49/69) | 50% (3/6) | 50% (10/20) | 65.26% (62/95) | |||
| Age | 0< Age ≤2M | 8.70% (6/69) | 33.33% (2/6) | 15% (3/20) | 11.58% (11/95) | ||
| 2M< Age ≤4M | 73.91% (51/69) | 33.33% (2/6) | 45% (9/20) | 65.26% (62/95) | |||
| 4M< Age ≤6M | 1.45% (1/69) | 16.67% (1/6) | 15% (3/20) | 5.26% (5/95) | |||
| >6M | 1.45% (1/69) | — | — | 1.05% (1/95) | |||
| Other enteric viruses in the CPV positive samples | CCoV | 24.64% (17/69) | 33.33% (2/6) | 10% (2/20) | 22.11% (21/95) | ||
| CaKV | 18.84% (13/69) | — | 5% (1/20) | 14.74% (14/95) | |||
| CBoV | 4.35% (3/69) | 16.67% (1/6) | 15% (3/20) | 7.37% (7/95) | |||
| CCoV+CaKV | 13.04% (9/69) | — | 5% (1/20) | 10.53% (10/95) | |||
| CBoV+CaKV | 1.45% (1/69) | — | 5% (1/20) | 2.11% (2/95) | |||
| CCoV+CBoV+CaKV | 1.45% (1/69) | — | — | 1.05% (1/95) | |||
| Identity | Nucleotides | New2a | 99.2%–100% | 99.2%–100% | 99.2%–100% | 99.0%–100% | |
| New2b | 99.6%–100% | 100% | — | 99.8%–100% | |||
| 2c | 100% | — | 100% | 100% | |||
| New2a+ New2b+2c | 98.8%–100% | 99.0%–100% | 98.6%–100% | 98.8%–100% | |||
| Amino acids | New2a | 98.8%–100% | 99.4%–100% | 99.4%–100% | 98.8%–100% | ||
| New2b | 100% | 100% | — | 100% | |||
| 2c | 100% | — | 100% | 100% | |||
| New2a+ New2b+2c | 97.6%–100% | 98.8%–100% | 98.2%–100% | 97.6%–100% | |||